27.(amended) A method for treating a condition that includes phosphorylation of proteins by a kinase, comprising,

administering to a subject an amount of the kinase binding molecule of claim 21 effective to inhibit the phosphorylation of the proteins by the kinase.

30.(amended) A kinase inhibitor comprising a binding motif for a phosphorylation site of a kinase identified according to claim 1, wherein the single non-degenerate phosphorylatable amino acid is replaced by an amino acid that cannot be phosphorylated by the kinase to which the inhibitor binds.

36.(amended) A composition comprising the kinase inhibitor of claim 30 and a pharmaceutically acceptable carrier.

38.(amended) A method for inhibiting phosphorylation of proteins by a kinase, comprising,

contacting the kinase with an amount of the kinase inhibitor of claim 30 effective to inhibit the phosphorylation.

39.(amended) A method for treating a condition that includes phosphorylation of proteins by a kinase, comprising,

administering to a subject an amount of the kinase inhibitor of claim 30 effective to inhibit the phosphorylation of the proteins by the kinase.

42.(amended) A method for validating a kinase as a target for inhibition for the treatment of a condition, comprising

providing a molecule comprising a binding motif for a phosphorylation site of a kinase as claimed in claim 1,

contacting a biological sample containing a kinase suspected of being involved in the causation of the condition with the molecule for a time sufficient to permit binding of the molecule and the kinase, and

determining the effect of the molecule on one or more biological processes mediated by the kinase.

46.(amended) A method for inhibiting a ZAP-70 kinase comprising,

contacting the ZAP-70 kinase with an amount of a kinase inhibitor as claimed in claim 30, effective to inhibit the ZAP-70 kinase.

48.(amended) A method for treating a condition mediated by a ZAP-70 kinase comprising

administering to a subject in need of such treatment an amount of a kinase inhibitor as claimed in claim 30, effective to inhibit the ZAP-70 kinase.

52.(amended) A method for inhibiting transcription mediated by a ZAP-70-responsive promoter sequence, comprising

contacting a biological sample, cell or organism that comprises a ZAP-70-responsive promoter sequence operably linked to a nucleic acid molecule with an amount of a kinase inhibitor as claimed in claim 30 effective to inhibit the transcription of the nucleic acid molecule mediated by the ZAP-70-responsive promoter sequence.

55.(amended) A method for treating a condition mediated by transcription mediated by a ZAP-70-responsive promoter sequence, comprising

administering to a subject in need of such treatment an amount of a kinase inhibitor as claimed in claim 30, effective to inhibit the transcription mediated by the ZAP-70-responsive promoter sequence.

60.(amended) A method for identifying a kinase inhibitor compound, comprising

providing a kinase, a kinase inhibitor that binds the kinase, and a candidate kinase inhibitor compound,

contacting the kinase with the candidate kinase inhibitor compound and the kinase inhibitor under conditions that permit binding of the kinase inhibitor to the kinase, wherein either or both of the candidate kinase inhibitor compound and the kinase inhibitor are detectable, and wherein either or both of the candidate kinase inhibitor compound and the kinase inhibitor comprises a sequence determined according to claim 1,

separating the kinase from the unbound kinase inhibitor and unbound candidate kinase inhibitor compound, and